<DOC>
	<DOCNO>NCT01331941</DOCNO>
	<brief_summary>This phase 1 , open-label pharmacokinetic study 40 subject advance solid tumor ( 6-10 normal renal function 18-30 varying degree renal dysfunction ) receive weekly dos AMG 386 intravenously . The primary objective evaluate pharmacokinetics ( PK ) single agent AMG 386 subject various degree renal function . Once AMG 386 PK characterization complete first 5 week study , subject allow continue receive AMG 386 weekly subject group 1 , 2 3 opt receive AMG 386 weekly combination paclitaxel disease progression , unacceptable toxicity withdrawal consent .</brief_summary>
	<brief_title>A Pharmacokinetic Study AMG 386 Cancer Subjects With Normal Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<criteria>Men woman ≥ 18 year age Must pathologically document , definitively diagnose , advance solid tumor refractory standard treatment , curative therapy available , subject refuse standard therapy Evaluable OR measurable disease RECIST 1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Life expectancy &gt; 3 month , opinion document investigator Subject subject 's legally acceptable representative provide informed consent Subjects gastric cancer malignancy purely squamous cell histology Known history primary central nervous system ( CNS ) tumor CNS metastases Myocardial infarction within 1 year study day 1 , unstable uncontrolled disease/condition relate affect cardiac function ( eg , unstable angina , congestive heart failure , New York Heart Association &gt; class II , uncontrolled hypertension [ diastolic &gt; 90 mmHg ; systolic &gt; 150 mmHg repeat measurement ] ) History stroke , arterial venous thrombosis , pulmonary embolism within 1 year study day 1 Active grade 2 great peripheral vascular disease peripheral edema History interstitial lung disease ( eg , pneumonitis pulmonary fibrosis ) Nonhealing wound , ulcer ( include gastrointestinal ) fracture Known positive test human immunodeficiency virus infection , active hepatitis B hepatitis C infection Major surgery within 4 week study day 1 Absolute neutrophil count ( ANC ) &lt; 1.0 x 10^9/L ; platelet count &lt; 100 x 10^9/L ; hemoglobin &lt; 9 g/dL ; PTT / aPTT &gt; 1.5 x institutional upper limit normal ( ULN ) ) ; INR &gt; 1.5 Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 x ULN ( &gt; 5.0 x ULN liver metastasis present ) Alkaline phosphatase &gt; 2.5 x ULN ( &gt; 5.0 x ULN attributable liver bone metastasis ) Total bilirubin &gt; 1.5 x ULN Other investigational procedure study Previous anticancer therapy investigational agent within 4 week prior study day 1 Anticoagulation therapy within 4 week study day 1 study ( except low dose warfarin ( ≤ 2 mg/kg ) prophylaxis central venous catheter thrombosis ) Men woman reproductive potential , unwilling practice highly effective method birth control duration study additional 6 month last dose AMG 386 . Highly effective method birth control include sexual abstinence ( men , woman ) ; vasectomy condom spermicide ( men ) combination barrier method , hormonal birth control IUD ( woman ) . Women lactating/breastfeeding . Women positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>AMG 386</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Renal Impairment</keyword>
</DOC>